Immutep Limited (NASDAQ:IMMP – Get Free Report) crossed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $2.28 and traded as low as $1.91. Immutep shares last traded at $1.95, with a volume of 48,963 shares.
Analyst Upgrades and Downgrades
Separately, Robert W. Baird decreased their price target on Immutep from $7.00 to $6.00 and set an “outperform” rating on the stock in a research note on Thursday, June 27th.
View Our Latest Research Report on IMMP
Immutep Trading Down 2.1 %
Institutional Trading of Immutep
A number of hedge funds and other institutional investors have recently modified their holdings of IMMP. BNP Paribas Financial Markets boosted its holdings in shares of Immutep by 15.4% during the 1st quarter. BNP Paribas Financial Markets now owns 35,300 shares of the biotechnology company’s stock valued at $82,000 after acquiring an additional 4,700 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of Immutep during the second quarter worth about $26,000. Virtu Financial LLC grew its holdings in shares of Immutep by 269.4% during the first quarter. Virtu Financial LLC now owns 45,062 shares of the biotechnology company’s stock worth $105,000 after purchasing an additional 32,864 shares during the last quarter. Oracle Investment Management Inc. raised its holdings in Immutep by 9.4% in the 1st quarter. Oracle Investment Management Inc. now owns 564,879 shares of the biotechnology company’s stock valued at $1,316,000 after buying an additional 48,449 shares during the last quarter. Finally, XY Capital Ltd acquired a new stake in Immutep during the 2nd quarter worth approximately $105,000. Institutional investors own 2.32% of the company’s stock.
Immutep Company Profile
Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.
Further Reading
- Five stocks we like better than Immutep
- Health Care Stocks Explained: Why You Might Want to Invest
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- Which Wall Street Analysts are the Most Accurate?
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- How to Start Investing in Real Estate
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for Immutep Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immutep and related companies with MarketBeat.com's FREE daily email newsletter.